scholarly journals Allogeneic Transplantation as Therapy for Acute Myelogenous Leukemia in the Elderly

2014 ◽  
Vol 20 (4) ◽  
pp. 437-438 ◽  
Author(s):  
Gary J. Schiller
Keyword(s):  
Acute Myelogenous Leukemia ◽  
The Elderly ◽  
Allogeneic Transplantation ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous

Aging, Acute Myelogenous Leukemia, and Allogeneic Transplantation: Do They Belong in the Same Sentence?

2009 ◽  
Vol 9 (4) ◽  
pp. 289-297 ◽  
Author(s):  
Stefan O. Ciurea ◽  
Morgani Rodrigues ◽  
Sergio Giralt ◽  
Marcos de Lima
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Allogeneic Transplantation ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous

Treating the Elderly Patient with Acute Myelogenous Leukemia

Hematology ◽  
2010 ◽  
Vol 2010 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Selina M. Luger
Keyword(s):  
Elderly Patient ◽  
Acute Myelogenous Leukemia ◽  
Intensive Therapy ◽  
Age Groups ◽  
The Elderly ◽  
Population Based ◽  
Myelogenous Leukemia ◽  
Best Interest ◽  
Related Factors ◽  
Acute Myelogenous

Abstract Decisions regarding the optimal treatment of acute myelogenous leukemia in the elderly patient requires the consideration of multiple factors. Population-based studies have demonstrated that, for all age groups, aggressive therapy results in improved survival and quality of life when compared with palliative care. The optimal induction and postremission regimen for older patients has yet to be determined. Furthermore, not all patients are candidates for such therapy. Consideration of patient and disease-related factors can help to determine the appropriateness of intensive therapy in a given patient. For those patients for whom aggressive induction therapy does not seem to be in their best interest, novel agents are being investigated that will hopefully address the issues of induction death and early relapse associated with these patient populations.

Sign in / Sign up

Export Citation Format

Share Document